Drug intelligence / Profile preview

Cerumol

Development stage: Unknown
Lead developer: Thornton & Ross
Modality: Small Molecules
Administration: Otic

Overview

Cerumol is an established over-the-counter (OTC) otic solution used for the softening and removal of impacted earwax (cerumen). The formulation typically contains a combination of chlorobutanol and paradichlorobenzene in a base of arachis oil (peanut oil). Chlorobutanol acts as a preservative with mild antibacterial and local anesthetic properties, while paradichlorobenzene serves as a cerumenolytic agent that helps to dissolve and loosen the wax. The arachis oil base further assists in lubricating the ear canal to facilitate the natural or manual removal of the softened wax. Cerumol is marketed by STADA Pharmaceuticals (through its subsidiary Thornton & Ross) and is indicated for use in adults, the elderly, and children.

Brand names: Cerumol
Other names: Cerumol Ear Drops

Beyond the preview

Go deeper on Cerumol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerumol.

Explore the full profile